STOCK TITAN

Candel Therapeutics, Inc. - CADL STOCK NEWS

Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.

Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.

Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.

Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.

Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.

Rhea-AI Summary

Candel Therapeutics, a late clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies, announced that CEO Paul Peter Tak will present at H.C. Wainwright’s Annual Global Investment Conference.

Date: May 24, 2022, Time: 7:00 am ET for on-demand viewing. Candel's leading candidates include CAN-2409 and CAN-3110, designed to induce immune responses against cancer. For more details, visit Candel Therapeutics’ website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
conferences
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) reported its Q1 2022 financial results and outlined key advancements in oncolytic viral immunotherapy for cancer. The company strengthened its cash position with a $20 million debt financing and reported cash equivalents of $94.3 million as of March 31, 2022. Research and development expenses rose to $5.4 million, reflecting increased clinical trial activities. Notably, the net loss decreased to $874,000 compared to $4.5 million in Q1 2021. Candel is set to present pivotal clinical data at the upcoming ASCO Annual Meeting in June 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the acceptance of an abstract for presentation at the ASCO Annual Meeting 2022, scheduled for June 3-7 at McCormick Place, Chicago. The abstract will present data from a phase 2 clinical trial on CAN-2409 and valacyclovir in combination with anti-PD-1/PD-L1 agents for treating stage III/IV NSCLC patients. Key details include:

  • Abstract Title: First report of safety/tolerability and preliminary antitumor activity of CAN-2409
  • Presenter: Charu Aggarwal
  • Date: June 6, 2022
  • Abstract Number: 9037
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
conferences
Rhea-AI Summary

Candel Therapeutics (CADL) reported a strong cash position of $82.6 million as of December 31, 2021, up from $35.1 million in 2020, bolstered by a successful IPO. Despite a net loss of $36.1 million for the year, the company plans to present key clinical trial data in 2022, seeking to advance its oncolytic viral immunotherapies for various cancers. Operating expenses increased to $25.9 million, driven by R&D and administrative costs linked to its growth strategy. Candel is positioned for critical milestones with upcoming data readouts expected in mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) has appointed Dr. Seshu Tyagarajan as the Chief Technical and Development Officer. Tyagarajan brings over 20 years of experience from Novartis, where she led CGT manufacturing strategies, including the BLA submission for Kymriah, the first FDA-approved CAR-T therapy. Her expertise in biologics manufacturing is expected to enhance Candel’s development efforts for oncolytic viral immunotherapy, which targets solid tumors. The company aims to leverage her insights to elevate its technical operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
management
-
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL) has secured a $25 million loan from Silicon Valley Bank, with $20 million available immediately and up to $5 million contingent on specific milestones. This financing extends the company's cash runway into Q4 2023, providing operational flexibility ahead of key clinical trials, including CAN-2409 and CAN-3110. CEO Paul Peter Tak highlights the attractive, non-dilutive terms of the loan as beneficial for upcoming data release and trial initiation, crucial for the company's oncolytic viral immunotherapy programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL) has appointed Francesca Barone, M.D., Ph.D., as its new Chief Scientific Officer. With over 20 years of expertise in immunology and drug development, Dr. Barone previously served as Candel's Vice President, Head of Research. She has substantial experience from her roles at Kintai Therapeutics and Senda Biosciences. Dr. Barone expressed optimism about the company's investigational immunotherapies aimed at treating cancer, emphasizing their unique ability to induce strong immune responses. This leadership change aims to enhance Candel's clinical development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
management
-
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company specializing in oncolytic viral immunotherapies, announced upcoming presentations at two virtual investor conferences in January 2022. Paul Peter Tak, CEO, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, with on-demand viewing starting at 7:00 am ET. He will also present live at the B. Riley Securities’ 2022 Oncology Conference on January 28, 2022, at 11:30 am ET. The company focuses on advancing cancer treatments through innovative engineered viruses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
conferences
-
Rhea-AI Summary

Bionaut Labs and Candel Therapeutics have formed a strategic collaboration to advance preclinical development of remote-controlled microscale robots for targeted delivery of oncolytic viral immunotherapies to brain tumors. Utilizing Bionaut’s precision medicine technology, the partnership aims to enhance therapeutic efficacy for high-grade glioma patients. Both companies will retain rights to their platforms while working together towards clinical trials. Terms of the agreement remain undisclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the Partnership for Accelerating Cancer Therapies (PACT) for a biomarker analysis in a phase 2 clinical trial targeting non-small cell lung cancer (NSCLC). The study will evaluate the efficacy of CAN-2409 combined with immune checkpoint inhibitors following inadequate responses to initial treatments. With three patient cohorts, the collaboration aims to identify early biological indicators of treatment response. This partnership enhances Candel's research credibility and aims to advance therapeutic options for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
partnership
Candel Therapeutics, Inc.

Nasdaq:CADL

CADL Rankings

CADL Stock Data

215.87M
38.51M
18.54%
44.13%
7.5%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEEDHAM